Published in Drug Week, April 23rd, 2004
The increase was attributable to higher sales of the Omnicarbon heart valve in the Middle East and in the United States. The third-quarter net loss was $1,328,051 or $0.15 per share, versus a loss of $1,083,216 or $0.14 per share, in the same period year ago. The increase in loss for the quarter versus year-ago can be primarily traced to interest expense for bridge loan debt executed during the first quarter.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.